|

Histiocytic Disorder Follow-up Study

RECRUITINGSponsored by University of Alabama at Birmingham
Actively Recruiting
SponsorUniversity of Alabama at Birmingham
Started2022-09-01
Est. completion2027-07
Eligibility
Age0 Years – 89 Years
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT05915208

Summary

The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

Eligibility

Age: 0 Years – 89 YearsHealthy volunteers accepted
Inclusion Criteria:

* diagnosis of histiocytic disorder at any age

  1. Langerhans cell histiocytosis,
  2. Erdheim-Chester disease,
  3. Rosai-Dorfman disease,
  4. Xanthogranuloma,
  5. Mixed histiocytosis
  6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)
  7. Hemophagocytic lymphohistiocytosis

Exclusion Criteria:

* None

Conditions8

CancerErdheim-Chester DiseaseHistiocytosisLangerhans Cell HistiocytosisLung CancerMalignant HistiocytosesRosai-Dorfman DiseaseXanthogranuloma

Locations1 site

University of Alabama at Birmingham
Birmingham, Alabama, 35233
Gaurav Goyal, MD1-866-438-1640histio@uabmc.edu

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.